Search results for "Anticoagulant therapy"
Amiodarone increases bleeding compared with flecainide or sotalol in patients on anticoagulant therapy
A retrospective analysis of Medicare patients who started an anticoagulant and then amiodarone found that they had a 44% increased risk for bleeding-related hospitalization compared to those on other antiarrhythmics and that this risk was higher with rivaroxaban than apixaban.
https://immattersacp.org/weekly/archives/2023/05/23/1.htm
23 May 2023
Take TIAs as seriously as a stroke
Internal medicine physicians play a critical role in educating patients about the seriousness of transient ischemic attacks and preventing their recurrence.
https://immattersacp.org/archives/2023/05/take-tias-as-seriously-as-a-stroke.htm
1 May 2023
MKSAP Quiz: Evaluation for right calf pain
A 24-year-old woman is evaluated for pain in the right calf since yesterday. She reports no shortness of breath, cough, or chest pain. Her medical history is unremarkable. Following a physical exam and ultrasound, what is the most appropriate management?
https://immattersacp.org/weekly/archives/2023/07/04/3.htm
4 Jul 2023
Coding for anticoagulation as tricky as managing it
Diagnosis, lab tests and management make up the three key considerations when coding for anticoagulation management through Medicare. An expert sorts out the issues and scenarios for a variety of scenarios.
https://immattersacp.org/archives/2010/05/practice.htm
1 May 2010
Higher risk for DVT, PE, bleeding seen after COVID-19; long-term risk for VTE recurrence may be low
A Swedish study found that patients who had COVID-19 were at higher risk for a first deep venous thrombosis (DVT) for up to three months, pulmonary embolism (PE) for up to six months, and bleeding for up to two months, while a single-center study from France found that risk for venous thromboembolism (VTE) recurrence up to a year after COVID-19 was low.
https://immattersacp.org/weekly/archives/2022/04/12/2.htm
12 Apr 2022
Task Force finds insufficient evidence on screening for afib
The U.S. Preventive Services Task Force reviewed trials published since 2017 but did not deem them strong enough to show evidence of benefit or harm.
https://immattersacp.org/weekly/archives/2022/02/01/3.htm
1 Feb 2022
Non-vitamin K oral anticoagulants appear superior to vitamin K antagonists in early-stage CKD
An accompanying editorial said that the current review supports a superior benefit profile of non-vitamin K oral anticoagulants (NOACs) in patients with atrial fibrillation and early-stage chronic kidney disease (CKD).
https://immattersacp.org/weekly/archives/2019/07/16/2.htm
16 Jul 2019
Low-molecular-weight heparin may not prevent VTE after knee arthroscopy or lower-leg casting, studies find
The Prevention of Thrombosis after Knee Arthroscopy (POT-KAST) and the Prevention of Thrombosis after Lower Leg Plaster Cast (POT-CAST) trials used the same methods and design to compare a prophylactic dose of low-molecular-weight heparin or no anticoagulant therapy.
https://immattersacp.org/weekly/archives/2016/12/13/4.htm
13 Dec 2016
Fixed-dose oral rivaroxaban appears noninferior to standard therapy for PE
Fixed-dose oral rivaroxaban is as effective as standard anticoagulant therapy for pulmonary embolism (PE) and may have a lower bleeding risk, a new study found.
https://immattersacp.org/weekly/archives/2012/03/27/5.htm
27 Mar 2012
IDSA offers criteria on testing for COVID-19; new research looks at clots, treatments
The Infectious Diseases Society of America (IDSA) released guidance for COVID-19 testing among inpatients and outpatients, while studies offered further support for anticoagulation but showed no benefit from hydroxychloroquine or lopinavir-ritonavir.
https://immattersacp.org/weekly/archives/2020/05/12/1.htm
12 May 2020